Reckitt Benckiser Korea releases Gaviscon
Published: 2009-11-06 06:56:00
Updated: 2009-11-06 06:56:00
Reckitt Benckiser Korea, a Korean unit of UK based Reckitt Benckiser plc, says it has recently launched Gasviscon, a non-prescription medication for the treatment of heartburn and GERED/(also known as GORD) (acid reflux).
Gaviscon is taken to treat heartburn, similar to other antacids. Gavisco...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
